Barclays analyst Matt Miksic raised the firm’s price target on Edwards Lifesciences to $100 from $90 and keeps an Overweight rating on the shares. The firm says that if the company’s strong sales momentum continues into the first half of 2024, it sees potential upward estimate revisions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target raised to $100 from $85 at Baird
- Edwards Lifesciences price target raised to $95 from $85 at Mizuho
- Edwards Lifesciences sees Q1 adjusted EPS 62c-66c, consensus 66c
- Edwards Lifesciences sees Q1 adjusted EPS 62c-66c, consensus
- Edwards Lifesciences backs FY24 adjusted EPS $2.70-$2.80, consensus $2.76
